{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-24-000006","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.557862+00:00","generated_at":"2026-06-05T07:31:02.307012+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lisata Therapeutics reports FY2023 net loss $20.8M; cash $50.5M; ASCEND trial on track for Q4 2024 data","bullets":["Net loss of $20.8M for FY2023 vs $54.2M in FY2022; operating expenses $25.7M (down 55% YoY).","Cash, cash equivalents, and marketable securities of $50.5M; runway projected into early 2026.","Phase 2b ASCEND trial in mPDAC fully enrolled; top-line data expected Q4 2024; complete data mid-2025.","R&D expenses $12.7M vs $13.1M prior year; G&A expenses $13.0M vs $14.1M.","Multiple Phase 2a trials ongoing (BOLSTER, CENDIFOX, iLSTA, GBM); Qilu licensee progressing in China."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-24-000006","json":"https://secwatch.observer/filing/0000320017-24-000006.json","markdown":"https://secwatch.observer/filing/0000320017-24-000006.md","text":"https://secwatch.observer/filing/0000320017-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001724000006/0000320017-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001724000006/clbs-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:31:02.307012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f9e5c6d1f59aa25a11cef4746ddbdf4d9a96e0d","claim":"LISATA THERAPEUTICS, INC. updated its twelve months ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the twelve months ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000032001724000006/0000320017-24-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}